GSK to cut up to 850 jobs
This article was originally published in Scrip
GlaxoSmithKline could cut up to 850 jobs in R&D in the UK and US, adding to the 350 losses made in the division in July. The company says that it has started consultation on the proposals, which will last for at least 90 days. This is part of ongoing measures announced in the third quarter of 2007 to improve effectiveness and efficiency. "We believe these changes are necessary as part of GSK's longer-term strategy to ensure that we can invest in key areas of future growth and evolve our business to compete effectively in what is a rapidly changing and challenging environment." GSK said that it was reviewing the entire business and was considering streamlining its manufacturing as part of the process.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.